La gratuité en santé. Mon oeil!
Free healthcare treatments. No way!

Click here to listen to radio spot

French radio ad to force the Quebec Government, by getting people to write to their deputy, to reimburse Lucentis for Quebec residents.

People were encouraged to visit CampagneMonOeil.ca where they could find an editable text in a web form to send directly to their deputy.

Ranibizumab (trade name Lucentis) is a monoclonal antibody fragment derived from the same parent murine antibody as bevacizumab (Avastin). It is much smaller than the parent molecule and has been affinity matured to provide stronger binding to VEGF-A. It is an anti-angiogenic that has been approved to treat the “wet” type of age-related macular degeneration (ARMD), a common form of age-related vision loss.

Ranibizumab was developed by Genentech and is marketed in the United States by Genentech and elsewhere by Novartis, under the brand name Lucentis.

More on Wikipedia

Brand name: CampagneMonOeil.ca for Lucentis
Generic name/category: Ranibizumab
Company: Novartis
Country/Market: Quebec province, Canada
Indication(s)/use: age-related macular degeneration (ARMD)
Target: Consumers (DTC)
Tagline: La gratuité en santé. Mon oeil!
Publication: Quebec radio stations may 2009